Efficacy of 5 MU of interferon in combination with ribavirin for naı̈ve patients with chronic hepatitis C virus: a randomized controlled trial

Association between mutations in the core region of hepatitis C virus genotype 1 and hepatocellular carcinoma development

“…We found the absence of an SVR and the non-DW-type pattern to be predictors of HCC development; however, the non-DW-type pattern was not a predictor of the absence of an SVR. This may be partly because we used IFN monotherapy without ribavirin, with which the SVR rate (26.5% in our study) was lower than that with peginterferon plus ribavirin [33,34]. Therefore, we believe that combination therapy, rather than IFN monotherapy, would more efficiently eradicate HCV with the DWtype pattern in the core region; however, further studies are required to test this hypothesis.…”

Effectiveness and cost-effectiveness of initial combination therapy with interferon/peginterferon plus ribavirin in patients with chronic hepatitis C in Germany: A health technology assessment commissioned by the German Federal Ministry of Health and Social Security

“…Twelve studies regarding the medical efficacy of combination therapy with interferon plus ribavirin compared to interferon monotherapy were included; herein 2 HTA reports [38], [39] 1 systematic Cochrane review [24], 2 meta-analyses [23], [40] and 7 controlled randomised clinical trials [41], [42], [43], [44], [13], [14], [45]. Two controlled randomised multicentre studies [15], [16] regarding medical efficacy of combination therapy with peginterferon and ribavirin compared to interferon plus ribavirin were identified and included.…”

“…Several randomised trials [41], [42], [43], [44], [13], [14], [45] and meta-analyses [23], [24], [40] reported combination therapy with interferon plus ribavirin to be more efficient than interferon monotherapy (SVR: 32-54% vs. 8-21%). Two randomised multicentre studies [15], [16] reported a higher SVR for peginterferon plus ribavirin compared to combination therapy with interferon plus ribavirin (54-56% vs. 44-47%).…”

Recombinant alfa-interferon plus ribavirin therapy in children and adolescents with chronic hepatitis C

“…For this reason the combination therapy has become standard treatment. [12][13][14][15][16] In the meantime the response rate in adults with chronic hepatitis C has been further improved with pegylated alfa-interferon in combination with ribavirin. 17,18 To date, none of these treatments has been approved for children and adolescents.…”